Analysts Issue Forecasts for Legend Biotech Q3 Earnings

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Free Report) – Research analysts at HC Wainwright decreased their Q3 2027 earnings estimates for Legend Biotech in a research report issued on Wednesday, November 11th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of $0.32 per share for the quarter, down from their prior forecast of $0.44. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($0.02) per share. HC Wainwright also issued estimates for Legend Biotech’s Q4 2027 earnings at $0.48 EPS.

A number of other brokerages have also weighed in on LEGN. JPMorgan Chase & Co. cut their price objective on Legend Biotech from $35.00 to $33.00 and set a “neutral” rating on the stock in a report on Friday, October 9th. Benchmark reaffirmed a “buy” rating on shares of Legend Biotech in a report on Tuesday, July 28th. Oppenheimer decreased their target price on Legend Biotech from $40.00 to $25.00 and set a “market perform” rating for the company in a report on Wednesday, November 11th. Morgan Stanley dropped their target price on Legend Biotech from $49.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 11th. Finally, Evercore downgraded shares of Legend Biotech from an “outperform” rating to an “in-line” rating and set a $20.00 price objective on the stock. in a report on Friday, November 13th. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Legend Biotech currently has an average rating of “Moderate Buy” and a consensus price target of $48.64.

Check Out Our Latest Stock Report on LEGN

Legend Biotech Stock Performance

Shares of LEGN opened at $16.25 on Thursday. The stock has a 50-day moving average of $19.30 and a two-hundred day moving average of $22.10. Legend Biotech has a one year low of $15.75 and a one year high of $37.50. The stock has a market cap of $3.15 billion, a P/E ratio of -1,623.38 and a beta of 0.55.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.13. The firm had revenue of $359.50 million for the quarter, compared to the consensus estimate of $361.46 million. Legend Biotech had a negative return on equity of 0.03% and a negative net margin of 0.02%. The firm’s revenue was up 32.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.05) EPS.

Institutional Investors Weigh In On Legend Biotech

Several hedge funds have recently bought and sold shares of LEGN. Assenagon Asset Management S.A. acquired a new stake in shares of Legend Biotech during the 2nd quarter worth approximately $55,307,000. Squarepoint Ops LLC lifted its stake in shares of Legend Biotech by 60.4% in the 2nd quarter. Squarepoint Ops LLC now owns 769,252 shares of the company’s stock valued at $22,216,000 after purchasing an additional 289,772 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Legend Biotech by 29.5% in the 1st quarter. Renaissance Technologies LLC now owns 521,800 shares of the company’s stock valued at $9,439,000 after purchasing an additional 119,000 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in Legend Biotech by 343.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 406,901 shares of the company’s stock worth $7,361,000 after buying an additional 315,176 shares in the last quarter. Finally, Tidal Investments LLC boosted its holdings in Legend Biotech by 34.0% during the second quarter. Tidal Investments LLC now owns 240,476 shares of the company’s stock worth $6,945,000 after buying an additional 61,023 shares in the last quarter. Hedge funds and other institutional investors own 70.89% of the company’s stock.

Insider Transactions at Legend Biotech

In other news, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the business’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $9.46, for a total value of $258,920.20. Following the completion of the transaction, the director owned 52,731 shares of the company’s stock, valued at $498,835.26. The trade was a 34.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Carlos Santos sold 5,430 shares of the company’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $9.14, for a total value of $49,630.20. Following the completion of the sale, the chief financial officer owned 14,246 shares in the company, valued at $130,208.44. The trade was a 27.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.02% of the company’s stock.

About Legend Biotech

(Get Free Report)

Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.

Recommended Stories

Earnings History and Estimates for Legend Biotech (NASDAQ:LEGN)

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.